People with eating disorders are taking GLP-1s and doctors are alarmed – The Washington Post

Medical professionals are raising alarms over the use of GLP-1 receptor agonists among individuals with a history of eating disorders. These medications, which include semaglutide and tirzepatide, are designed to treat type 2 diabetes and obesity by mimicking hormones that signal fullness to the brain and slowing gastric emptying.

While these drugs are effective for weight management in general populations, doctors report that they may be dangerous for patients struggling with restrictive eating patterns. The primary concern is that the biological appetite suppression provided by GLP-1s can reinforce the psychological drive to avoid food, potentially exacerbating eating disorder symptoms.

The Risk of Biological Reinforcement

For individuals with eating disorders, the ability to suppress hunger is often a goal of the disorder itself. GLP-1 medications achieve this biologically, which can create a feedback loop that validates restrictive behaviors. When the physical sensation of hunger is removed, patients may find it easier to maintain dangerously low caloric intakes without the biological distress that usually accompanies starvation.

these medications can mask the symptoms of an active eating disorder. Because the drug causes weight loss and suppresses appetite, a patient may appear to be responding successfully to a medical treatment for obesity while they are actually engaging in restrictive eating patterns. This masking effect can make it difficult for clinicians to distinguish between medication-induced weight loss and a relapse into an eating disorder.

Gaps in Clinical Screening

Reporting from The Washington Post indicates that many patients are obtaining these medications without rigorous psychiatric screening. While the labels for these drugs may contain warnings, the rapid increase in prescriptions for weight loss has led to gaps in how providers screen for a history of eating disorders.

The lack of comprehensive screening means that individuals with a predisposition to disordered eating may be prescribed medications that fundamentally alter their relationship with hunger, and satiety. Medical experts emphasize the need for a multidisciplinary approach, involving both endocrinologists and mental health professionals, before initiating GLP-1 therapy in patients with a history of restrictive eating.

Vulnerability in Older Populations

The risk extends to older adults, a demographic where eating disorders are frequently underdiagnosed or overlooked. Older populations may face unique nutritional challenges, and the use of GLP-1s can increase the risk of malnutrition or muscle loss if weight loss is not carefully monitored by a healthcare provider.

When appetite suppression is combined with the natural decline in appetite that can occur with age, the risk of severe nutritional deficiencies increases. This makes the intersection of GLP-1 use and disordered eating particularly precarious for seniors.

Medical Context and Monitoring

GLP-1 receptor agonists are powerful tools for managing metabolic health, but their application requires a nuanced understanding of a patient’s psychological history. The medical community is calling for a higher standard of care that prioritizes mental health stability alongside weight loss goals.

Key areas of concern for monitoring patients on these medications include:

• The emergence of obsessive behaviors regarding food intake or calorie counting.
• Rapid weight loss that exceeds healthy clinical targets.
• The disappearance of hunger cues that may lead to unintentional malnutrition.
• A history of anorexia, bulimia, or binge-eating disorder that was not disclosed during the initial consultation.

As these medications become more integrated into standard obesity treatment, the focus is shifting toward ensuring that the pursuit of weight loss does not come at the expense of psychological health or the stability of those in recovery from eating disorders.